In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

Merck (NYSE:MRK) has agreed to acquire Terns Pharmaceuticals in a deal aimed at expanding its oncology and hematology ...

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...

March 25 () - Merck said on Wednesday it would buy biotech Terns ‌Pharma in a deal valued ‌at up to $6.7 billion, as the ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...

Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

Two stocks retirement investors typically reach for in uncertain markets have risen notably in recent months. Is it too late to buy?

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...